# A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care

> **NCT07742527** · PHASE1 · NOT_YET_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 22 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Belantamab SC
- **DRUG:** Belantamab IV
- **DRUG:** Recombinant Human Hyaluronidase PH20 (rHuPH20)
- **DRUG:** Standard of care

## Key facts

- **NCT ID:** NCT07742527
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-16
- **Primary completion:** 2027-08-05
- **Final completion:** 2030-03-18
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07742527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07742527, "A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07742527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*